Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853812 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL18561538 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL471157 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL14853864 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL18561535 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL12799387 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL13486961 | 1.00 | ABL1 (0.58) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL14262781 | 0.90 | ABL1 (0.60) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL17684780 | 0.89 | ABL1 (0.57) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL18289200 | 0.89 | ABL1 (0.57) | ABL1RIN1POLBP2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9452154-B2 | Methods for treating HCV | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452154-B2 | Methods for treating HCV | GILEAD SCIENCES, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150141353-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141353-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20090274686-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | ABL1 643/4885RIN1 4496/4885POLB 1708/4885 |
| US-20160354425-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | ABL1 245/4885RIN1 4036/4885POLB 2735/4885 |
| US-20130273005-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | ABL1 245/4885RIN1 4036/4885POLB 2735/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | ABL1 245/4885RIN1 4036/4885POLB 2735/4885 |
| US-20150141353-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | ABL1 245/4885RIN1 4036/4885POLB 2735/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | ABL1 245/4885RIN1 4036/4885POLB 2735/4885 |
| US-20090274686-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES | ENTPD5, PNP, TYMP | ABL1 681/4885RIN1 3163/4885POLB 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.